These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21393354)

  • 1. Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study.
    Yano Y; Hoshide S; Tamaki N; Nagata M; Sasaki K; Kanemaru Y; Shimada K; Kario K
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):340-7. PubMed ID: 21393354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
    Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
    Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
    Williams GH; Burgess E; Kolloch RE; Ruilope LM; Niegowska J; Kipnes MS; Roniker B; Patrick JL; Krause SL
    Am J Cardiol; 2004 Apr; 93(8):990-6. PubMed ID: 15081441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
    Prisant LM; Krum H; Roniker B; Krause SL; Fakouhi K; He W
    J Clin Pharmacol; 2003 Nov; 43(11):1203-10. PubMed ID: 14551174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of aldosterone blockade.
    Weber MA
    Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.
    Elnagar N; Satoh M; Hosaka M; Asayama K; Ishikura K; Obara T; Mano N; Ohkubo T; Imai Y
    Clin Exp Hypertens; 2014; 36(2):83-91. PubMed ID: 24625334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
    Bayorh MA; Mann G; Walton M; Eatman D
    Clin Exp Hypertens; 2006 Feb; 28(2):121-32. PubMed ID: 16546838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant responses to two classes of drugs acting on the renin-angiotensin system.
    Sever PS; Chang CL
    J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):25-30. PubMed ID: 11881062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.
    Suzuki H; Shuto H; Shuto C; Ohara I; Inokuma S; Abe Y; Sukigara M
    Ther Adv Cardiovasc Dis; 2012 Aug; 6(4):141-7. PubMed ID: 22751654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rats: the role of the renin-angiotensin-aldosterone system.
    Kamari Y; Shimoni N; Koren F; Peleg E; Sharabi Y; Grossman E
    J Hypertens; 2010 Jan; 28(1):95-101. PubMed ID: 19770680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.